Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Early Reversibility of Rocuronium After Different Doses of Neostigmine

NCT00001520 is registered in ClinicalTrials.gov with National Institutes of Health Clinical Center (CC) as lead sponsor.

NCT NCT00001520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00001520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Early Reversibility of Rocuronium After Different Doses of Neostigmine
Lead sponsor
National Institutes of Health Clinical Center (CC)
Phase
Phase 4
Overall status
Completed
Start date
September 30, 1996
Completion date
August 31, 2000
Enrollment
60
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

paralysis